Physician profile
Amy C James
NPI 1972549426
$2,112.18
in general payments reported to CMS, 2019-2025
21 companies · $275 in 2025
The $275 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $444 · 2020: $99.25 · 2021: $85.97 · 2022: $201 · 2023: $452 · 2024: $555 · 2025: $275.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,282.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,281.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $351.76 | 2019-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Lilly USA, LLC | $300.39 | 2019-2025 | Jardiance, Zepbound, Mounjaro |
| Pfizer INC. | $213.58 | 2019-2024 | |
| Novo Nordisk INC | $207.10 | 2019-2025 | Ozempic, Wegovy |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $147.70 | 2023-2024 | Caplyta |
| Exact Sciences Corporation | $123.02 | 2023-2025 | Cologuard Collection Kit |
| Astrazeneca Pharmaceuticals Lp | $103.01 | 2019-2023 | Farxiga |
| Astellas Pharma US INC | $75.90 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $74.92 | 2022-2025 | Jardiance, Synjardy |
| Abbvie INC. | $70.83 | 2021-2025 | |
| Insulet Corporation | $65.35 | 2023-2024 | Omnipod |
| Novartis Pharmaceuticals Corporation | $64.90 | 2023-2025 | |
| Dexcom, INC. | $64.66 | 2023-2025 | Dexcom G6 Transmitter |
| Ironshore Pharmaceuticals INC. | $60.19 | 2019 | |
| Janssen Pharmaceuticals, INC | $37.45 | 2019-2021 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $34.91 | 2024 | |
| Axsome Therapeutics, INC. | $32.93 | 2025 | Auvelity |
| Ultragenyx Pharmaceutical INC. | $27.83 | 2022-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $26.69 | 2020-2023 | Xifaxan |
| Allergan, INC. | $14.86 | 2020 | |
| Hologic Sales and Service, LLC | $14.20 | 2024 | Aptima |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy James listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.